Prevention and treatment of osteoporosis in women: an update
Obstetrics, Gynaecology and Reproductive Medicine, 05/14/2012
Daroszewska A – Anabolic therapy with PTH peptides is currently reserved for severe osteoporosis. A number of novel treatments e.g. cathepsin K inhibitors, calcilytic drugs anti–sclerostin antibodies are being assessed in clinical trials.
- A postmenopausal woman has an approximately 50% lifetime risk of suffering an osteoporotic fracture with hip fractures carrying the highest morbidity and mortality.
- Non–pharmacological prevention strategies focus on attainment and maintenance of a high peak bone mass and include a healthy lifestyle, nutritious and balanced diet, maintenance of optimal vitamin D level and physical exercise with skeletal mechanical loading.
- Pharmacological interventions include hormone replacement therapy in women with early menopause and postmenopausal women until the age of 60 in the absence of contraindications.
- Bisphosphonates (e.g. alendronate, risedronate and zoledronate) remain the mainstay of antiresorptive treatment and the novel biologic antiresorptive agent, denosumab is a safe option in patients intolerant or with contraindications to bisphosphonates.